BR0314299A - Derivados de pirrolidona como inibidores de mao-b - Google Patents

Derivados de pirrolidona como inibidores de mao-b

Info

Publication number
BR0314299A
BR0314299A BR0314299-0A BR0314299A BR0314299A BR 0314299 A BR0314299 A BR 0314299A BR 0314299 A BR0314299 A BR 0314299A BR 0314299 A BR0314299 A BR 0314299A
Authority
BR
Brazil
Prior art keywords
inhibitors
mao
derivatives
pyrrolidone derivatives
pyrrolidone
Prior art date
Application number
BR0314299-0A
Other languages
English (en)
Inventor
Hans Iding
Daniela Krummenacher
Rosa Maria Rodriguez Sarmiento
Andrew William Thomas
Beat Wirz
Wolfgang Wostl
Rene Wyler
Synese Jolidon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0314299A publication Critical patent/BR0314299A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE PIRROLIDONA COMO INIBIDORES DE MAO-B". A presente invenção refere-se a derivados de 4-pirrolidino racêmicos enantiomericamente puros de fórmula I, processos para a sua preparação, composições farmacêuticas compreendendo ditos derivados, e seu uso na prevenção e tratamento de enfermidades, em particular as que são mediadas por inibidores de monoamina oxidase B, em particular a doença de Alzheimer ou demência senil.
BR0314299-0A 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b BR0314299A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20
PCT/EP2003/010384 WO2004026827A1 (en) 2002-09-20 2003-09-18 Pyrrolidone derivatives as maob inhibitors

Publications (1)

Publication Number Publication Date
BR0314299A true BR0314299A (pt) 2005-12-13

Family

ID=32010924

Family Applications (4)

Application Number Title Priority Date Filing Date
BR0314314-7A BR0314314A (pt) 2002-09-20 2003-09-18 Derivados do éter 4-pirrolidina-fenil-benzìlico
BR0314631-6A BR0314631A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de maob
BR0314299-0A BR0314299A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b
BRPI0314631-6A BRPI0314631B1 (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b, seu uso, e composição farmacêutica

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR0314314-7A BR0314314A (pt) 2002-09-20 2003-09-18 Derivados do éter 4-pirrolidina-fenil-benzìlico
BR0314631-6A BR0314631A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de maob

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0314631-6A BRPI0314631B1 (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b, seu uso, e composição farmacêutica

Country Status (32)

Country Link
US (4) US7235581B2 (pt)
EP (3) EP1542970B1 (pt)
JP (3) JP4335142B2 (pt)
KR (3) KR100676014B1 (pt)
CN (3) CN100383118C (pt)
AR (3) AR041299A1 (pt)
AT (2) ATE472530T1 (pt)
AU (3) AU2003273901B2 (pt)
BR (4) BR0314314A (pt)
CA (3) CA2498785C (pt)
CY (1) CY1110745T1 (pt)
DE (2) DE60333202D1 (pt)
DK (1) DK1542970T3 (pt)
ES (2) ES2344557T3 (pt)
GT (3) GT200300204A (pt)
HK (3) HK1084383A1 (pt)
HR (3) HRP20050263B1 (pt)
JO (2) JO2605B1 (pt)
MX (3) MXPA05002878A (pt)
MY (3) MY134480A (pt)
NO (3) NO330012B1 (pt)
NZ (3) NZ538049A (pt)
PA (3) PA8583001A1 (pt)
PE (3) PE20050077A1 (pt)
PL (3) PL376018A1 (pt)
PT (1) PT1542970E (pt)
RU (3) RU2336267C2 (pt)
SI (1) SI1542970T1 (pt)
TW (3) TWI286132B (pt)
UY (3) UY27991A1 (pt)
WO (3) WO2004026827A1 (pt)
ZA (3) ZA200501137B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
BRPI0514077A (pt) * 2004-08-02 2008-05-27 Hoffmann La Roche derivados de benzilóxi como inibidores de maob
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
AU2006224878B2 (en) * 2005-03-15 2011-02-17 F. Hoffman-La Roche Ag Method for preparing enantiomerically pure 4-pyrrolidinophenyl benzyl ether derivatives
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
DE602006015215D1 (de) * 2005-10-10 2010-08-12 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
CA2706017A1 (en) * 2007-03-30 2008-10-09 Jorge R. Barrio In vivo imaging of sulfotransferases
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
CA2895287A1 (en) 2013-03-14 2014-10-02 Dart Neuroscience, Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
RU2016118748A (ru) * 2013-10-29 2017-12-05 Ф. Хоффманн-Ля Рош Аг Кристаллические формы производного пирролидона, полезные при лечении болезни альцгеймера, и их получение
WO2016102967A1 (en) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
EP3273946A1 (en) * 2015-03-27 2018-01-31 F. Hoffmann-La Roche AG Pharmaceutical formulation comprising sembragiline
US11365194B2 (en) 2017-09-27 2022-06-21 Kagoshima University Analgesic drug using PAC1 receptor antagonistic drug
CN112153968A (zh) 2017-10-05 2020-12-29 生物基因公司 制备α-羧酰胺吡咯烷衍生物的工艺
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
CN110240557B (zh) * 2018-03-08 2023-05-09 广东东阳光药业有限公司 吡咯烷酰胺衍生物及其用途
EP3932490A4 (en) 2019-02-27 2022-11-16 Kagoshima University ANTIPRURIC AGENT USING PAC1 RECEPTOR ANTAGONISTS
WO2021225161A1 (ja) 2020-05-08 2021-11-11 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) * 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
ES2087097T3 (es) 1989-04-19 1996-07-16 Otsuka Pharma Co Ltd Derivados de acidos fenilcarboxilicos que contienen un heterociclo.
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
JP3258027B2 (ja) 1996-03-15 2002-02-18 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレジリン投与による末梢ニューロパシーの予防および治療方法
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
CA2361848A1 (en) * 1999-04-02 2000-10-12 Dupont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
AU1359801A (en) 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
BR0108182B1 (pt) * 2000-02-10 2010-06-29 aparelho para o tratamento de incontinência urinária com suprimento de energia sem fio.
US7442165B2 (en) * 2000-02-14 2008-10-28 Obtech Medical Ag Penile prosthesis
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism

Also Published As

Publication number Publication date
RU2005111969A (ru) 2006-01-20
KR20050057466A (ko) 2005-06-16
PE20050078A1 (es) 2005-02-28
ES2338646T3 (es) 2010-05-11
TWI331994B (en) 2010-10-21
HRP20050263A2 (en) 2006-12-31
DE60331559D1 (de) 2010-04-15
US20040097578A1 (en) 2004-05-20
BR0314631A (pt) 2005-08-02
ATE459601T1 (de) 2010-03-15
KR20050057450A (ko) 2005-06-16
WO2004026827A1 (en) 2004-04-01
UY27990A1 (es) 2004-03-31
MY135696A (en) 2008-06-30
US20060122235A1 (en) 2006-06-08
CN1681777A (zh) 2005-10-12
AU2003270213B2 (en) 2009-02-12
NO20050701L (no) 2005-03-02
KR20050057456A (ko) 2005-06-16
AR041298A1 (es) 2005-05-11
PE20050079A1 (es) 2005-03-01
HRP20050261A2 (en) 2006-05-31
JP2006510596A (ja) 2006-03-30
AR041297A1 (es) 2005-05-11
KR100676014B1 (ko) 2007-01-30
TW200408624A (en) 2004-06-01
RU2005111968A (ru) 2006-11-10
NO329754B1 (no) 2010-12-13
JP4335142B2 (ja) 2009-09-30
RU2323209C2 (ru) 2008-04-27
MY133332A (en) 2007-11-30
CA2498785A1 (en) 2004-04-01
US7037935B2 (en) 2006-05-02
NO330012B1 (no) 2011-02-07
SI1542970T1 (sl) 2010-08-31
AU2003273901B2 (en) 2008-07-10
PT1542970E (pt) 2010-07-19
RU2005111974A (ru) 2006-01-20
PA8583501A1 (es) 2004-04-23
WO2004026826A1 (en) 2004-04-01
BRPI0314631B1 (pt) 2018-04-17
JP2006503833A (ja) 2006-02-02
BR0314314A (pt) 2005-07-26
JP4335141B2 (ja) 2009-09-30
JO2605B1 (en) 2011-11-01
CA2498785C (en) 2011-07-26
GT200300204A (es) 2004-04-29
RU2336268C2 (ru) 2008-10-20
US20040106650A1 (en) 2004-06-03
DK1542970T3 (da) 2010-08-02
CN1681778A (zh) 2005-10-12
US20040116707A1 (en) 2004-06-17
PA8583001A1 (es) 2004-04-23
CY1110745T1 (el) 2015-06-10
EP1542970B1 (en) 2010-06-30
GT200300206A (es) 2004-04-29
PE20050077A1 (es) 2005-03-01
AU2003267381A1 (en) 2004-04-08
TWI286132B (en) 2007-09-01
HRP20050263B1 (hr) 2013-09-30
US7235581B2 (en) 2007-06-26
EP1542969A1 (en) 2005-06-22
PL376018A1 (en) 2005-12-12
US7151111B2 (en) 2006-12-19
HK1084383A1 (en) 2006-07-28
TWI337604B (en) 2011-02-21
CA2498335A1 (en) 2004-04-01
CA2496756C (en) 2012-01-10
PL376019A1 (en) 2005-12-12
MY134480A (en) 2007-12-31
WO2004026825A1 (en) 2004-04-01
PA8583601A1 (es) 2004-09-16
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
GT200300205A (es) 2004-04-29
CN100503562C (zh) 2009-06-24
UY27993A1 (es) 2004-03-31
ES2344557T3 (es) 2010-08-31
RU2336267C2 (ru) 2008-10-20
NZ538049A (en) 2007-05-31
TW200413350A (en) 2004-08-01
HK1083498A1 (en) 2006-07-07
JP4335140B2 (ja) 2009-09-30
NO20050652L (no) 2005-03-08
NZ538048A (en) 2007-05-31
AU2003267381B2 (en) 2009-08-27
DE60333202D1 (de) 2010-08-12
AU2003273901A1 (en) 2004-04-08
ZA200501311B (en) 2006-10-25
KR100676015B1 (ko) 2007-01-30
CN100400509C (zh) 2008-07-09
MXPA05002880A (es) 2005-05-27
NZ538046A (en) 2007-08-31
HK1083499A1 (en) 2006-07-07
JP2006503834A (ja) 2006-02-02
MXPA05002878A (es) 2005-05-27
ZA200501137B (en) 2006-12-27
US7122562B2 (en) 2006-10-17
ATE472530T1 (de) 2010-07-15
EP1542971A1 (en) 2005-06-22
ZA200501557B (en) 2005-09-08
HRP20050262A2 (en) 2006-06-30
UY27991A1 (es) 2004-03-31
AU2003270213A1 (en) 2004-04-08
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
AU2003270213B8 (en) 2009-03-05
JO2604B1 (en) 2011-11-01
CN100383118C (zh) 2008-04-23
NO20050665L (no) 2005-04-18
TW200410935A (en) 2004-07-01
PL376021A1 (en) 2005-12-12
CA2496756A1 (en) 2004-04-01
AR041299A1 (es) 2005-05-11
CN1681779A (zh) 2005-10-12
KR100681586B1 (ko) 2007-02-09

Similar Documents

Publication Publication Date Title
BR0314299A (pt) Derivados de pirrolidona como inibidores de mao-b
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BRPI0416989A (pt) derivados aminopirazole como inibidores gsk-3
BRPI0413860A (pt) [1,8]naftiridin-2-onas e compostos relacionados para o tratamento de esquizofrenia
BR0312232A (pt) Inibidores de caspases e seus usos
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
BR0308786A (pt) Derivados de ftalimido como inibidores da monoamina oxidase b
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico
BRPI0415842A (pt) derivativos de benzapepina como inibidores de mao-b
BR0317714A (pt) Oxazóis como realçadores de mglur1
BR0313543A (pt) 2,3-diidro-isoindol-1-onas com atividade de inibição de mao-b
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
BRPI0512404A (pt) inibidores de mao-b
DE502007006951D1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE50302825D1 (de) 2-methylthiazolidin-2,4-dicarbonsaeure und deren salze zur behandlung von neurodegenerativen erkrankungen

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: BASEADO NO ART. 216 1 DA LPI, APRESENTE COPIA AUTENTICADA DA PROCURACAO PARA QUE ESTA SEJA ACEITA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2272 DE 22/07/2014.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI